Who are the potential patients for omalizumab for food allergy?

Sampson, Hugh A; Bird, J Andrew; Fleischer, David; Shreffler, Wayne G; Spergel, Jonathan M

Sampson, Hugh A; Bird, J Andrew; Fleischer, David; Shreffler, Wayne G; Spergel, Jonathan M.

Afiliação

Sampson HA; Division of Pediatric Allergy and Immunology, Jaffe Food Allergy Institute, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York.
Bird JA; Division of Allergy and Immunology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.
Fleischer D; Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.
Shreffler WG; Division of Pediatric Allergy and Immunology and Food Allergy Center, Massachusetts General Hospital, Boston, Massachusetts.
Spergel JM; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: spergel@chop.edu.

Ann Allergy Asthma Immunol ; 132(5): 569-571, 2024 05.

Article em En | MEDLINE | ID: mdl-38479711

Assuntos

Antialérgicos; Hipersensibilidade Alimentar; Omalizumab; Humanos; Omalizumab/uso terapêutico; Hipersensibilidade Alimentar/tratamento farmacológico; Antialérgicos/uso terapêutico; Imunoglobulina E/imunologia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antialérgicos / Omalizumab / Hipersensibilidade Alimentar Limite: Humans Idioma: En Revista: Ann Allergy Asthma Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google